AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6089858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 40
Study 6089858 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 31100611 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (20 sessions for 12 weeks)
Number of subjects: 170
Study 31100611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg for 8 weeks)
Number of subjects: 170
Study 31100611 — intervention group
Group type: COMPARATOR
Intervention: Sham for group D
Number of subjects: 170
Study 31100611 — intervention group
Group type: COMPARATOR
Intervention: Sham for group B
Number of subjects: 170
Study 31100611 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (20 sessions for 4 weeks)
Number of subjects: 170
Study 30196397 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (75 to 125 mg)
Number of subjects: 12
Study 30196397 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 12
Study 26753808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass to the nearest neuroscience centre (NC)
Number of subjects: 293
Study 26753808 — intervention group
Group type: COMPARATOR
Intervention: Selective secondary transfer to NSAH
Number of subjects: 293
Study 26753808 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day mortality
Number of subjects: 293
Study 26753808 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month Extended Glasgow Outcome Scale (GOSE)
Number of subjects: 293
Study 26753808 — intervention group
Group type: EXPERIMENTAL
Intervention: European Quality of Life-5 Dimensions
Number of subjects: 293
Study 26753808 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway acceptability to patients, families, and staff
Number of subjects: 293
Study 24147757 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop-signal training
Number of subjects: 0
Study 24147757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dieting implementation intentions
Number of subjects: 0
Study 24147757 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions
Number of subjects: 0
Study 24147757 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 22647800 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session educational program, 'Celiac School', based on problem-based learning
Number of subjects: 106
Study 22647800 — intervention group
Group type: COMPARATOR
Intervention: Information regarding celiac disease sent at home
Number of subjects: 106
Study 19383986 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounded omeprazole
Number of subjects: 30
Study 19383986 — intervention group
Group type: EXPERIMENTAL
Intervention: Manufactured omeprazole
Number of subjects: 30
Study 17725245 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 960 mg
Number of subjects: 114
Study 17725245 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 1,920 mg
Number of subjects: 114
Study 17725245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 114
Study 16038522 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/sulbactam
Number of subjects: 62
Study 16038522 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 62
Study 12048095 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (group I) with continuous infusion of bupivacaine 0.125% and 2mg fentanyl/ml at a dosage of 6-10 ml per hour for 5 days.
Number of subjects: 30
Study 12048095 — intervention group
Group type: COMPARATOR
Intervention: Intercostal nerve block (group II) with 20 ml 0.5% bupivacaine applied at the end of the operation.
Number of subjects: 30
Study 10401013 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol-grafted cellulose (PGC) membranes
Number of subjects: 63
Study 10401013 — intervention group
Group type: COMPARATOR
Intervention: Cuprophane membranes
Number of subjects: 63
Study 10401013 — intervention group
Group type: EXPERIMENTAL
Intervention: Both membranes (PGC and cuprophane)
Number of subjects: 63
Study 7743697 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (enalapril)
Number of subjects: 0
Study 7743697 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilator therapy (hydralazine/isosorbide dinitrate)
Number of subjects: 0
Study 7743697 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2106369 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic breast cancer screening with mammography and clinical examination
Number of subjects: 60000
Study 2106369 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60000
Study 6166347 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide group (semisynthetic polysulphated xylan)
Number of subjects: 86
Study 6166347 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70 group
Number of subjects: 86
Study 6166347 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study 31328363 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 antagonist exendin 9-39
Number of subjects: 40
Study 31328363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31328363 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric emptying study
Number of subjects: 40
Study 31328363 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 40
Study 28344139 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function (defined as a >20% reduction in estimated glomerular filtration rate from discharge to 6 months, or progression to macroalbuminuria)
Number of subjects: 2776
Study 28344139 — intervention group
Group type: COMPARATOR
Intervention: Stable renal function
Number of subjects: 2776
Study 28344139 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function
Number of subjects: 2776
Study 26509639 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucopolysaccharide hemospheres (MPH)
Number of subjects: 48
Study 26509639 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC) gel
Number of subjects: 48
Study 26509639 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato starch wafer
Number of subjects: 48
Study 24722351 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB
Number of subjects: 49
Study 24722351 — intervention group
Group type: EXPERIMENTAL
Intervention: rMenB
Number of subjects: 49
Study 24722351 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB (40 and 42 months)
Number of subjects: 49
Study 24722351 — intervention group
Group type: COMPARATOR
Intervention: Control (before immunization)
Number of subjects: 49
Study 24722351 — intervention group
Group type: COMPARATOR
Intervention: Control (after immunization)
Number of subjects: 49
Study 23047822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg intravenously at days 1 and 15, plus standard chemotherapy)
Number of subjects: 171
Study 23047822 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (3 + 7)
Number of subjects: 171
Study 23047822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg intravenously at days 1 and 15, plus cytarabine 1000 mg/m(2) twice daily on days 1‐6)
Number of subjects: 171
Study 23047822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab arm
Number of subjects: 171
Study 23047822 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 171
Study 19571250 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐hr tobacco deprivation (n = 51)
Number of subjects: 212
Study 19571250 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum smoking (n = 69)
Number of subjects: 212
Study 19571250 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐hr tobacco deprivation
Number of subjects: 212
Study 19571250 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum smoking
Number of subjects: 212
Study 17304449 — intervention group
Group type: EXPERIMENTAL
Intervention: Sb(v) plus oral pentoxifylline for 30 days
Number of subjects: 23
Study 17304449 — intervention group
Group type: COMPARATOR
Intervention: Sb(v) plus oral placebo
Number of subjects: 23
Study 15193908 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min exercise break involving moderate intensity, low-impact aerobic dance and calisthenic movements to music
Number of subjects: 449
Study 15193908 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min exercise break
Number of subjects: 449
Study 15193908 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 449
Study 11515595 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 0
Study 11515595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9609365 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental history of hypertension
Number of subjects: 3250
Study 9609365 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental history of diabetes
Number of subjects: 3250
Study 9609365 — intervention group
Group type: COMPARATOR
Intervention: Parental hypertension
Number of subjects: 3250
Study 9609365 — intervention group
Group type: COMPARATOR
Intervention: Proliferative retinopathy
Number of subjects: 3250
Study 8001358 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention with a minimum of four visits at home by a trained health worker providing emotional support and health education.
Number of subjects: 2235
Study 8001358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 2235
Study 3281387 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 35
Study 3281387 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant-only preparation
Number of subjects: 35
Study 5317541 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol aerosol (0.65 mg per dose, taken as required several times daily)
Number of subjects: 134
Study 5317541 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol aerosol (average treatment duration of about four months)
Number of subjects: 134
Study 5317541 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol oral tablets (20 to 80 mg daily for an average of about three weeks)
Number of subjects: 134
Study 31838056 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing statement: severe, life-threatening
Number of subjects: 1961
Study 31838056 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing statement: serious
Number of subjects: 1961
Study 31838056 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing statement: basic
Number of subjects: 1961
Study 31465685 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term storage red cells
Number of subjects: 1693
Study 31465685 — intervention group
Group type: COMPARATOR
Intervention: Long-term storage red cells
Number of subjects: 1693
Study 28844039 — intervention group
Group type: EXPERIMENTAL
Intervention: External stressors (radio noise and a distractive scripted family member)
Number of subjects: 30
Study 28844039 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no external stressors)
Number of subjects: 30
Study 26152418 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside/Praziquantel solution (3 mg/kg emodepside and 12 mg/kg praziquantel)
Number of subjects: 16
Study 26152418 — intervention group
Group type: COMPARATOR
Intervention: Placebo spot-on (control group)
Number of subjects: 16
Study 21884030 — intervention group
Group type: EXPERIMENTAL
Intervention: R-BNP
Number of subjects: 11
Study 21884030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 21884030 — intervention group
Group type: COMPARATOR
Intervention: Levosimendan
Number of subjects: 11
Study 21522069 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate Milk (CM)
Number of subjects: 10
Study 21522069 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 10
Study 21522069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 19025665 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 200
Study 19025665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 16527396 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity electroacupuncture (to tolerance but sub-noxious)
Number of subjects: 48
Study 16527396 — intervention group
Group type: COMPARATOR
Intervention: Placebo electroacupuncture (using Streitberger placebo needle)
Number of subjects: 48
Study 16527396 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electrical stimulation, placebo needles)
Number of subjects: 48
Study 16527396 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity electroacupuncture (strong but comfortable)
Number of subjects: 48
Study 12881011 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 67
Study 12881011 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture (vitamin C, vitamin E, and a-lipoic-acid)
Number of subjects: 67
Study 12881011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 10792132 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand-guided intubation through the intubating laryngeal mask airway
Number of subjects: 120
Study 10792132 — intervention group
Group type: COMPARATOR
Intervention: Blind intubation through the intubating laryngeal mask airway
Number of subjects: 120
Study 9495936 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic rinse
Number of subjects: 15
Study 9495936 — intervention group
Group type: COMPARATOR
Intervention: Control rinse
Number of subjects: 15
Study 7680732 — intervention group
Group type: EXPERIMENTAL
Intervention: Following-the-child's-lead condition
Number of subjects: 3
Study 7680732 — intervention group
Group type: COMPARATOR
Intervention: Recruiting-the-child's-attention condition
Number of subjects: 3
Study 3485398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nifedipine
Number of subjects: 20
Study 3485398 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline
Number of subjects: 20
Study 30412065 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand therapy with esomeprazole 40 mg
Number of subjects: 80
Study 30412065 — intervention group
Group type: COMPARATOR
Intervention: Continuous therapy with esomeprazole 20 mg
Number of subjects: 80
Study 28157463 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 539
Study 28157463 — intervention group
Group type: COMPARATOR
Intervention: Any TB incidence
Number of subjects: 539
Study 28157463 — intervention group
Group type: COMPARATOR
Intervention: Any TB incidence before ART initiation
Number of subjects: 539
Study 28157463 — intervention group
Group type: COMPARATOR
Intervention: Any TB incidence <180 days after ART initiation
Number of subjects: 539
Study 28157463 — intervention group
Group type: COMPARATOR
Intervention: Any TB incidence ≥180 days after ART initiation
Number of subjects: 539
Study 25546704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB) or intra-aortic balloon pump (IABP)
Number of subjects: 2525
Study 25546704 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned CPB or IABP
Number of subjects: 2525
Study 25546704 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergent CPB or IABP
Number of subjects: 2525
Study 25546704 — intervention group
Group type: COMPARATOR
Intervention: No CPB or IABP
Number of subjects: 2525
Study 21744061 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical activity intervention
Number of subjects: 140
Study 21744061 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercises alone (Control Group)
Number of subjects: 140
Study 19919569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day combined with peginterferon (Peg‐IFN)‐alpha‐2b/ribavirin (RBV) for 48 weeks
Number of subjects: 97
Study 19919569 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Peg‐IFN‐alpha‐2b/RBV for 48 weeks)
Number of subjects: 97
Study 18990058 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus type 5 (Ad5)‐vectored clade B HIV‐1 monovalent gag and trivalent gag/pol/nef vaccines
Number of subjects: 406
Study 18990058 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus type 5 (Ad5)‐vectored clade B HIV‐1 vaccines with >or=1 x 10(10) gag‐containing Ad5 particles per dose
Number of subjects: 406
Study 18990058 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus type 5 (Ad5)‐vectored clade B HIV‐1 vaccines
Number of subjects: 406
Study 16893966 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol dose
Number of subjects: 134
Study 16893966 — intervention group
Group type: COMPARATOR
Intervention: Sober participants
Number of subjects: 134
Study 16893966 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sexual arousal influenced by alcohol consumption and expectancies
Number of subjects: 134
Study 12682876 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (STI571)
Number of subjects: 0
Study 12682876 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Number of subjects: 0
Study 12682876 — intervention group
Group type: COMPARATOR
Intervention: Interferon‐alfa (IFN‐alpha)
Number of subjects: 0
Study 12682876 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (HU)
Number of subjects: 0
Study 12682876 — intervention group
Group type: COMPARATOR
Intervention: Alkylating agents
Number of subjects: 0
Study 11051345 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.i.d.) for 2 weeks followed by clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) for 1 week
Number of subjects: 30
Study 11051345 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg b.i.d.) for 2 weeks followed by clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) for 1 week
Number of subjects: 30
Study 11051345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg b.i.d.) for 2 weeks followed by clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) for 1 week
Number of subjects: 30
Study 9325828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive polymeric film dressing A
Number of subjects: 100
Study 9325828 — intervention group
Group type: COMPARATOR
Intervention: Adhesive polymeric film dressing B
Number of subjects: 100
Study 7902225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold compression dressings
Number of subjects: 90
Study 7902225 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cold compression)
Number of subjects: 90
Study 3979000 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazoxiben (100 mg, intravenously every 4 hours for a maximum of 72 hours)
Number of subjects: 10
Study 3979000 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously every 4 hours for a maximum of 72 hours)
Number of subjects: 10
Study 3979000 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazoxiben
Number of subjects: 10
Study 3979000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31594739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate
Number of subjects: 768
Study 31594739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pink lady
Number of subjects: 768
Study 31594739 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap suds
Number of subjects: 768
Study 31594739 — intervention group
Group type: EXPERIMENTAL
Intervention: Other
Number of subjects: 768
Study 29903505 — intervention group
Group type: EXPERIMENTAL
Intervention: IGRT (arm 1)
Number of subjects: 57
Study 29903505 — intervention group
Group type: EXPERIMENTAL
Intervention: IGRT + HDR (arm 2)
Number of subjects: 57
Study 26745226 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise for 8 weeks
Number of subjects: 81
Study 26745226 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 81
Study 24720918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg/day
Number of subjects: 192
Study 24720918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 22578518 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline chemotherapy (mean dose, 296 ± 103 mg/m²)
Number of subjects: 19
Study 20880151 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol loading dose administered over 3.0 min (4 mg·kg(‐1))
Number of subjects: 50
Study 20880151 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 200 mcg·kg(‐1)·min(‐1) for 5 min or until respiratory insufficiency observed
Number of subjects: 50
Study 18602657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks requiring varied degrees of lexical processing (1-4 words displayed)
Number of subjects: 0
Study 18602657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks requiring significant lexical processing
Number of subjects: 0
Study 18602657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks that do not require significant lexical processing
Number of subjects: 0
Study 11322207 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU of interferon (IFN) tiw plus ribavirin (1000‐1200 mg/daily) for 12 months
Number of subjects: 192
Study 11322207 — intervention group
Group type: COMPARATOR
Intervention: 5 MU of interferon (IFN) tiw monotherapy
Number of subjects: 192
Study 9130939 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib polysaccharide tetanus protein (PRP-T) mixed with diphtheria-tetanus-pertussis vaccine (DTP)
Number of subjects: 42848
Study 9130939 — intervention group
Group type: COMPARATOR
Intervention: DTP alone
Number of subjects: 42848
Study 8433727 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate angioplasty
Number of subjects: 108
Study 8433727 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic agent (tissue plasminogen activator)
Number of subjects: 108
Study 8433727 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate angioplasty and thrombolytic agent
Number of subjects: 108
Study 3314973 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg, 5 times a day for 5 days
Number of subjects: 60
Study 3314973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3314973 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg
Number of subjects: 60